Scholar Rock resubmits apitegromab application to EMA for spinal muscular atrophy
SRRK•Scholar Rock resubmitted its marketing authorisation application for apitegromab to the European Medicines Agency for children and adults with spinal muscular atrophy, and anticipates a CHMP opinion in the first half of 2027.
1. Application resubmitted
Scholar Rock resubmitted its marketing authorisation application for apitegromab to the European Medicines Agency for treatment of children and adults with spinal muscular atrophy. The company anticipates a CHMP opinion on the application in the first half of 2027.
